You are here

DEVELOPMENT OF A NONINVASIVE GLUCOSE MONITOR

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44DK057362-02
Agency Tracking Number: DK057362
Amount: $989,475.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
VIVASCAN CORPORATION 560C PROSPECT ST
WEST BOYLSTON, MA 01583
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HANNU HARJUNMAA
 (508) 852-1600
 HARJUNMAA@EARTHLINK.NET
Business Contact
 ROBERT PEURA
Phone: (508) 852-1600
Email: RPEURA@AOL.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The goal of this project is to develop a portable, noninvasive, personal blood glucose monitor. VivaScan has developed and successfully tested a laboratory prototype instrument based on the Optical Bridge TM (OB) method. The OB uniquely nulls out the background absorption of the sample, overcoming the major problem of optical blood glucose measurements. Our successful Phase I diabetic patient study produced 96% of the measurement data in the clinically acceptable A and B zones of the Clarke error grid. The aims for Phase II include: 1) enhance electronics with microcontroller; 2) redesign and miniaturize the optics and device mechanics; 3) investigate the use of optical interference filters for acousto-optical tunable filters (AOTF) substitutes; 4) replace expensive AOTF, used for wavelength generation, with less expensive devices; 5) further enhance the glucose measurement algorithms; and 6) build four portable devices and test their performance with patients. Overall, the goal of the proposed work is to extend our laboratory prototype system to a patient oriented device, with improved accuracy, portability, ease of operation and affordability. Subsequent FDA approval of a practical portable in-home blood glucose monitor will be sought, allowing diabetic patients to noninvasively and painlessly monitor their glucose levels throughout the day.
PROPOSED COMMERCIAL APPLICATIONS:
Our market analysis suggests that from 500,000 to 4.4 million diabetic individuals could use a non-invasive glucose monitor. The global market would increase these projections by a factor of 2 or more.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government